CHICAGO, July 21 /PRNewswire-FirstCall/ -- Today at the American Association for Clinical Chemistry’s Clinical Lab Expo in Chicago, Abbott (NYSE: ABT - News) announced the launch of a new diagnostic instrument -- the ARCHITECT® c4000® clinical chemistry analyzer which performs diagnostic tests that monitor general health including a patient’s levels of sodium, potassium, chloride and organ function.
The new ARCHITECT c4000 seamlessly integrates with Abbott’s i1000SR immunoassay analyzer to form the ARCHITECT ci4100(TM), an automated analyzer that completes both immunoassay and chemistry tests on one platform. With these two products, Abbott now offers chemistry, immunoassay, and integrated diagnostic testing solutions to improve the performance and efficiency of laboratories of all sizes.
Abbott’s family of ARCHITECT instruments generates accurate and equivalent results across instruments and labs, even at multiple sites, because these instruments share detection technologies, reagents, and software. This standardization is critical as hospitals and the Obama administration continue to emphasize the importance of capturing patient histories in electronic medical records. In a recent study of U.S. hospitals, 73 percent of health care decision makers and executives identified electronic medical records (EMR) as one of their top priorities for 2009.
In addition to standardization across instruments, Abbott’s ARCHITECT c4000 and ci4100 are designed to deliver improved productivity to lower volume laboratories. The c4000 analyzer can generate up to 800 test results per hour while the ci4100 integrated system can generate up to 900 test results per hour. With an extensive menu of diagnostic tests and a large sample and reagent load-up capacity, the ARCHITECT c4000 and ci4100 can consolidate a laboratory’s workload to increase efficiency and save costs. ARCHITECT instruments are simple to operate with advanced sample management capabilities from the innovative three-dimensional Robotic Sample Handler. With this feature, once manual steps are now automated, which saves laboratories time and money and better meets their increased testing demands.
“We evaluated the ARCHITECT c4000 with one of our partner laboratories and found that the ARCHITECT c4000 provides laboratory efficiencies with commonality and equivalent results across the family,” said Rob Kerekes, chemistry charge technologist at Huron-Perth Healthcare Alliance in Stratford, Ontario, Canada. “The c4000 is ideal for laboratories requiring a reliable analyzer that takes up less space.”
About Abbott Diagnostics
Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott’s diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company’s commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements, including the development of the very first diagnostic test to detect HIV.
Abbott’s news releases and other information are available on the company’s Web site at www.abbott.com.
SOURCE Abbott
CONTACT: Media, Ann Fahey-Widman, +1-847-938-6388, or Financial, Tina
Ventura, +1-847-935-9390, both of Abbott
Web site: http://www.abbott.com/
